News
Researchers at MIT and other institutions have identified compounds that can fight off viral infection by activating a ...
A new antibody shot that protects babies against RSV infection could be struggling to gain traction, Philadelphia researchers ...
A new CHOP study found only one in three eligible patients took Beyfortus when the medication that protects against severe ...
“Appropriate people at higher risk should be vaccinated, and this will not only benefit the vaccinated person, but will ...
2d
Cryptopolitan on MSNOpenEden and Ceffu Launch First Yield-Bearing Collateral on MirrorRSVInstitutional clients can use cUSDO, OpenEden Digital’s yield-bearing digital asset, as collateral on MirrorRSV while ...
Shifts in RSV testing methodology, which were accelerated by changes related to the COVID-19 pandemic, mirror shifts seen in ...
Researchers at Washington University School of Medicine in St. Louis have revealed the structure of a key protein involved in ...
3d
Zacks Small Cap Research on MSNNNVC: NanoViricides Set to Initiate Phase 2 Trial in MPoxNNVC NanoViricides, Inc. (NYSE:NNVC) is a clinical-stage biopharmaceutical company developing a new class of broad-spectrum ...
British drugmaker GSK said on Monday it had submitted an application to the U.S. Food and Drug Administration to extend the ...
As summer kicks into full gear and people are spending more time outside, there's one thing on many people's minds—ticks.
In a twist, researchers at the University of Virginia and the National Institutes of Health uncovered a new organelle, dubbed the hemifusome. This tiny membrane-bound structure serves as a cellular ...
Gilead has blamed the low rate of respiratory syncytial virus infections last season for ending two midstage trials of obeldesivir.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results